Non-small cell lung cancer (nsclc) Trials in Houston, United States
Conditions / Non-small cell lung cancer (nsclc) / Houston, United States
Non-small cell lung cancer (nsclc) has been the subject of sustained clinical investigation across multiple research sites.
35 total trials for this combination
Showing top 10 of 35 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | RECRUITING | PHASE1/PHASE2 |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | RECRUITING | PHASE2 |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | RECRUITING | — |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | RECRUITING | — |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | RECRUITING | — |
| NCT07361497 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) | RECRUITING | — |
| NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | RECRUITING | — |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING | — |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING | — |